CD68

Across TCGA pan-cancer cohorts, CD68 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD68 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD68 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD68 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where CD68 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.164	0.812	.026	14	view →
LSCC	OS	Median	All	0.695	0.869	.022	5	view →
HNSC	DFS	Median	IV	0.904	0.612	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD68–CCRCC (OS)

Open the CCRCC breakdown →